A multicenter, randomized, two-armed, open-label Phase III study to evaluate the vaccination with tumor RNA-loaded autologous dendritic cells versus observation of patients with resected monosomy 3 uveal melanoma
Phase 3
Recruiting
- Conditions
- ChoroidC69.3uveal melanoma
- Registration Number
- DRKS00009784
- Lead Sponsor
- niversitätsklinikum Erlangen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Monosomy 3
Exclusion Criteria
Metastases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prolongation of Disease Free Survival
- Secondary Outcome Measures
Name Time Method Prolongation of Overall Survival